Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors

Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors

Whether Human Epidermal growth factor Receptor 2 (HER2)-low status has prognostic significance in HR + /HER2- advanced Breast Cancer (aBC) patients treated with first-line Endocrine Therapy plus CDK 4/6 inhibitors remains unclear. In 428 patients evaluated, HER2-low status was independently associat...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:NPJ breast cancer 2023-04, Vol.9 (1), p.27-27, Article 27
Hauptverfasser: Zattarin, Emma, Presti, Daniele, Mariani, Luigi, Sposetti, Caterina, Leporati, Rita, Menichetti, Alice, Corti, Chiara, Benvenuti, Chiara, Fucà, Giovanni, Lobefaro, Riccardo, Ligorio, Francesca, Provenzano, Leonardo, Vingiani, Andrea, Del Vecchio, Marta, Griguolo, Gaia, Sirico, Marianna, Bernocchi, Ottavia, Marra, Antonio, Zagami, Paola, Agostinetto, Elisa, Jacobs, Flavia, Di Mauro, Pierluigi, Esposito, Andrea, Giorgi, Carlo Alberto, Lalli, Luca, Boldrini, Laura, Giacchetti, Pier Paolo Berton, Schianca, Ambra Carnevale, Guarneri, Valentina, Pedersini, Rebecca, Losurdo, Agnese, Zambelli, Alberto, Generali, Daniele, Criscitiello, Carmen, Curigliano, Giuseppe, Pruneri, Giancarlo, de Braud, Filippo, Dieci, Maria Vittoria, Vernieri, Claudio
Format: Artikel
Sprache:eng
Schlagworte:
692/4028/67/1347
692/4028/67/1857
Biomarkers
Biomedical and Life Sciences
Biomedicine
Breast cancer
Brief Communication
Cancer Research
Cell Biology
Endocrine therapy
Epidermal growth factor
Human Genetics
Medical research
Metastasis
Oncology
Patients
Tumors
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Whether Human Epidermal growth factor Receptor 2 (HER2)-low status has prognostic significance in HR + /HER2- advanced Breast Cancer (aBC) patients treated with first-line Endocrine Therapy plus CDK 4/6 inhibitors remains unclear. In 428 patients evaluated, HER2-low status was independently associated with significantly worse PFS and OS when compared with HER2-0 status. Based on our findings, HER2-low status could become a new prognostic biomarker in this clinical setting.
ISSN:2374-4677
2374-4677
DOI:10.1038/s41523-023-00534-1